The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.
 
Philipp K. Haber
Patents, Royalties, Other Intellectual Property - Patent
 
Miguel Torres-Martin
No Relationships to Disclose
 
Jean-Francois Dufour
Consulting or Advisory Role - Abbvie; Bayer; Bristol-Myers Squibb; Falk Pharma; GENFIT; Genkyotex; Gilead Sciences; Lilly; Merck; Novartis; Roche
Research Funding - Gilead Sciences
 
Chris Verslype
Consulting or Advisory Role - Bayer; Ipsen; Novartis
Speakers' Bureau - BAYER
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Bayer; Ipsen
 
Jens Marquardt
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Ipsen; Janssen; Merz GmbH; MSD Oncology; Roche
Research Funding - Bayer (Inst); Leap Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; Ipsen; Merz GmbH
 
Peter R. Galle
Honoraria - Adaptimmune; Bayer Schering Pharma; Bristol-Myers Squibb; Ipsen; Lilly; MSD; Roche/Genentech; Sirtex Medical
Consulting or Advisory Role - Adaptimmune; Bayer Schering Pharma; Bristol-Myers Squibb; Lilly; MSD; Roche/Genentech; Sirtex Medical
Speakers' Bureau - Bayer Schering Pharma; Ipsen; Lilly; Roche
Travel, Accommodations, Expenses - Bayer Schering Pharma; Lilly; Sirtex Medical
 
Arndt Vogel
Honoraria - Amgen; Bristol-Myers Squibb; Ipsen; Janssen; Lilly; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Baxalta; Bayer; BTG; Eisai; IPSEN; Lilly; Novartis; Pierre Fabre; Roche
Research Funding - Novartis
Travel, Accommodations, Expenses - Bayer; Ipsen; Roche
 
Tim Meyer
Consulting or Advisory Role - Beigene; Bristol-Myers Squibb; BTG; Eisai; Ipsen; MSD; Roche
Research Funding - Bayer (Inst); BTG (Inst); Ipsen (Inst)
 
Ismail Labgaa
No Relationships to Disclose
 
Lewis R. Roberts
Consulting or Advisory Role - Bayer (Inst); Biocompatibles (Inst); Exact Sciences (Inst); GRAIL (Inst); QED Therapeutics (Inst); RedHill Biopharma (Inst); TAVEC (Inst)
Speakers' Bureau - Bayer
Research Funding - ARIAD (Inst); BTG (Inst); Exact Sciences (Inst); Gilead Sciences (Inst); Glycotest (Inst); RedHill Biopharma (Inst); Wako Diagnostics (Inst)
Patents, Royalties, Other Intellectual Property - Five Prime Therapeutics. Royalties (Inst); Five Prime Therapeutics. Royalties.; US Patent No. 9,469,877: Materials and Methods for Diagnosis, Prognosis, Monitoring of Recurrence and Assessment of Therapeutic/Prophylactic Treatment of Pancreaticobiliary Cancer (Inst)
Travel, Accommodations, Expenses - Gilead Sciences
 
Beatriz Minguez
No Relationships to Disclose
 
Vincenzo Mazzaferro
No Relationships to Disclose
 
Fabian Finkelmeier
No Relationships to Disclose
 
Tobias Müller
No Relationships to Disclose
 
Moritz Schmelzle
Honoraria - Amgen; Bayer; Erbe Elektromedizin; Merck
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CStone Pharmaceuticals; Eisai; Exelixis; Genentech/Roche; Lilly; Merck; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Expert Testimony - Bayer
 
Swan Thung
No Relationships to Disclose
 
Augusto Villanueva
Consulting or Advisory Role - Boehringer Ingelheim; Exact Sciences; Gilead Sciences; Guidepoint Global; Natera; NGM Biopharmaceuticals
Patents, Royalties, Other Intellectual Property - Patent EP20140382535 on a method for prognosis of hepatocellular carcinoma; Patent pending PCT/US2018/037579 on methods for the detection and treatment of classes of hepatocellular carcinoma responsive to immunotherapy; Patent US13124487 on compositions, kits, and methods for identification, assessment, prevention, and therapy of hepatic disorders; Small unannotated, non-coding RNAs for the detection of liver cancer
 
Daniela Sia
Patents, Royalties, Other Intellectual Property - None
 
Josep M Llovet
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Celsion; Eisai; Exelixis; Fortress Biotech; Genentech; Glycotest; Ipsen; Leerink; Lilly; Merck; Mina Alpha Ltd; Nucleix; Roche; Sirtex Medical
Research Funding - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Ipsen